Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Oxygen saturation in pregnant individuals with COVID-19: time for re-appraisal?

Joe Eid, MD; David Stahl, MD; Maged M. Costantine, MD; Kara M. Rood, MD

Introduction and Current Guidelines
During pregnancy, several professional societies recommend maintaining O₂ saturation (SpO₂) at ≥95%. In response to the current COVID-19 pandemic, the Society for Maternal-Fetal Medicine (SMFM) recommends that the target SpO₂ for pregnant individuals should be higher than recommended for the nonpregnant population (SpO₂≥92%). Furthermore, they recommend that inpatient monitoring should be considered for pregnant individuals with moderate or severe signs or symptoms of COVID-19 and for those whose SpO₂ drop below 95% while on room air during exertion. These patients should call their healthcare provider, undergo prompt evaluation, and be considered for inpatient admission, because they may require admission to higher level of care units such as an intensive care unit or a step-down unit.

Other professional societies such as the Royal College of Obstetricians and Gynaecologists and the International Federation of Gynecology and Obstetrics have advocated for the maintenance of SpO₂ at a similar cutoff of ≥95%.

Managing pregnant individuals with acute respiratory disease secondary to COVID-19 has been a challenge. Most professional societies including the Society for Maternal-Fetal Medicine recommend keeping O₂ saturation at ≥95% in pregnant individuals. Reaching this target has been increasingly difficult in some patients, especially during the latest wave of infections attributed to the delta variant of SARSCoV-2. In the absence of adequate supporting data, and in the setting of a reassuring fetal status, we propose that maternal O₂ saturation should be maintained between 92% and 96% for admitted patients with acute respiratory failure who require supplemental O₂. This may prevent unnecessary invasive interventions that might not hold maternal or fetal benefit, specifically at very preterm gestational ages.

Key words: COVID-19, oxygen saturation, pregnancy

However, the evidence supporting maintenance of SpO₂ at this cutoff is limited. Meanwhile, the World Health Organization suggests maintaining SpO₂ at 92% to 95% in pregnant individuals with severe respiratory infection secondary to COVID-19. What is the Evidence Behind Using an O₂ Saturation of ≥95%?

There are no published trials or clinical studies demonstrating that an SpO₂ at or above 95% is necessary for pregnant individuals to maintain adequate fetal oxygenation. Expert opinions suggest initiating supplemental O₂ for pregnant individuals when their SpO₂ falls below 94%, and this is based on known physiological changes that occur during pregnancy such as an increase in the partial pressure of O₂ (PaO₂) and increased O₂ demand. Some of the current guidelines that suggest maintaining an SpO₂ of ≥95% cite a paper published by Bhatia et al. These authors state that a PaO₂ of 70 mm Hg is required to maintain adequate fetal oxygenation, which they also associate with a maternal SpO₂ of 95%. Bhatia et al make this conclusion on the basis of a study by Catanzarite et al who included 28 women with acute respiratory distress syndrome (ARDS) who required intubation during pregnancy or within 1 week postpartum. This study is limited because it used the older definition of ARDS, included patients only if they were intubated and within 7 days of delivery, and used the birth outcome of perinatal asphyxia, on the basis of historic data, to indicate a causal mechanism of neonatal hypoxia. Applying these data to modern guidelines ignores >20 years of progress that has been made in the management of ARDS and confounding conditions such as the high rate of maternal multisystem organ failure. Although evidence from severe acute respiratory syndrome and COVID-19 suggests that there is a higher rate of fetal growth restriction in cases with severe maternal illness, this is likely multifactorial instead of being limited to hypoxemia as the cause. There is no compelling objective evidence that an SpO₂ of 95% is required for adequate fetal oxygenation.

Mallampali et al recommend maintaining the maternal PaO₂ above 60 to 70 mm Hg to avoid adverse effects on uteroplacental perfusion. However, other experts suggest that a PaO₂ of >60 mm Hg (correlating with an SpO₂ of >90%) is a reasonable target for pregnant individuals with acute respiratory failure. This is because fetal hemoglobin has a higher affinity for O₂ than adult hemoglobin,
which makes the fetus more resistant to changes in maternal O₂ saturation and some degree of hypoxia.¹⁵,¹⁶

Further support that a PaO₂ of 60 mm Hg is adequate for fetal O₂ delivery is on the basis of data from pregnant individuals living at high altitudes.¹⁷ Although this is a chronic rather than acute exposure to hypoxia (and is accompanied by compensation such as tachypnea and relative polycythemia), most of the pregnant individuals are young and healthy and have a good reserve to tolerate even acute hypoxia.¹⁸

In an effort to decrease maternal morbidity and mortality, early warning models have been developed to assist in the timely recognition of acutely ill patients,¹⁹–²¹ with some models including SpO₂ as one of the parameters.¹⁹,²⁰ Unlike other vital sign parameters that could directly be associated with an increased risk for maternal morbidity, the use of SpO₂ at <95% was not (relative risk 1.3; 95% confidence interval, 0.2–7.9).¹⁹ Shields et al.²¹ published a maternal early warning tool using different cutoffs for SpO₂. They used an SpO₂ of <90% as a single severe parameter and an SpO₂ of <93% as a nonsevere parameter. However, low SpO₂ (whether <90% or <93%) was a rare occurrence and was seen in <0.1% of included patients.²² In conclusion, the paucity of clinical data and lack of significance seen in early warning models do not provide sufficient evidence to support using an SpO₂ of ≥95% as a cutoff for pregnant individuals presenting with acute respiratory distress.

### Challenges in Maintaining an O₂ Saturation of ≥95%

In nonpregnant individuals with acute respiratory failure secondary to COVID-19, current guidelines recommend starting supplemental O₂ when levels drop below an SpO₂ of 90% (strong recommendation, moderate-quality evidence) and suggest supplemental O₂ use when SpO₂ falls below 92% (weak recommendation, low-quality evidence).²² In acutely ill patients, high-quality evidence showed that liberal O₂ therapy (median baseline SpO₂ of 96%) is associated with increased mortality.²² Moreover, practice guidelines for acutely ill patients, including COVID-19 patients with acute hypoxemic respiratory failure, do not recommend administration of supplemental O₂ above an SpO₂ of 96% (strong recommendation, moderate-quality evidence) because it may lead to worse outcomes.²²–²⁴ In pregnant individuals, Pacheco et al.²¹ also recommend that O₂ therapy should be titrated to avoid SpO₂ levels above 96%. Using a minimum target of 95% for SpO₂ in pregnancy would make it more difficult to titrate O₂ supplementation to avoid an SpO₂ of >96%.

There is a paucity of data to guide the O₂ goals when COVID-19 progresses to ARDS. Generally, the goal is to maintain PaO₂ at 55 to 80 mm Hg on the basis of extrapolation from the original ARDSNet trial²⁵ and more recent use in the ACURASYS²⁶ and Reevaluation of Systemic Early Neuromuscular Blockade²⁷ trials. Although there may be phenotypes of COVID-19–associated ARDS that respond to high amounts of noninvasive supplemental O₂ support, such as heated high-flow nasal cannula, many of these patients will require invasive mechanical ventilation.²⁸,²⁹ Indeed, some emerging data suggest that noninvasive positive-pressure ventilation (continuous positive airway pressure or bi-level positive airway pressure) may increase mortality and fail to decrease the rates of intubation in critically ill COVID-19 patients.³⁰ Other modern therapies for ARDS, such as prone positioning, have been used as alternative interventions to avoid invasive mechanical ventilation and improve oxygenation in COVID-19 patients.³¹,³² However, these therapies present unique challenges for pregnant individuals.

The criteria to mechanically ventilate pregnant and nonpregnant individuals are similar. These include airway protection, hypoxia, hypercarbia, and hemodynamic instability.¹⁵ Pregnant individuals infected with the SARS-CoV-2 delta variant are more frequently critically ill, requiring O₂ support more often compared with infection with previous variants.³³,³⁴ In pregnant individuals with acute respiratory failure secondary to COVID-19, guidelines suggest to maintain a target maternal SpO₂ of ≥95% as per professional societies recommendations, whereas for nonpregnant patients, often a target PaO₂ of 55 to 80 mm Hg or an SpO₂ of >90% is recommend. To meet this higher goal, pregnant individuals may need increased O₂ delivery by noninvasive O₂ delivery methods, earlier intubation and mechanical ventilation, increasing fraction of inspired O₂, mean airway pressure, or positive end-expiratory pressure. In addition, pregnant individuals will have cephalad displacement of the diaphragm, increased intraabdominal pressure, which provides mechanical evidence of a disadvantage of oxygenation, and an increased O₂ consumption by the developing fetus. This increased oxygenation target is difficult to achieve, especially in patients with COVID-19 affected by the latest wave of infections attributed to the delta variant of SARS-CoV-2.³³,³⁵ Thus, pregnant patients may be more likely to be exposed to increased invasive interventions when maternal oxygenation goals of 95% are unable to be maintained using noninvasive methods of O₂ supplementation, with potential risks and without clear maternal or fetal benefit.

In its guidance for managing COVID-19 patients, the SMFM suggests delivery at or after 32 weeks’ gestation in settings of refractory maternal hypoxemia.¹ Although an SpO₂ cutoff of ≥95% seems reasonable and safe as a target, in most clinical situations, challenges in treating pregnant individuals affected by the most recent COVID-19 wave have raised questions regarding the validity of this recommendation, especially for patients at extreme preterm gestational ages. Designing a randomized controlled trial comparing the clinical outcomes for patients who were maintained at O₂ saturation levels of 92% and 95 %, respectively, would be ideal and might be warranted. However, designing and completing such a trial in a timely fashion with the current COVID-19 wave is unrealistic. Individualized patient care based on maternal clinical
status and gestational age is of utmost importance.

External Fetal Monitoring as a Noninvasive Tool
Fetal oxygenation depends on maternal oxygenation and placental perfusion. Significant disturbances in maternal oxygenation may lead to fetal hypoxia, which is often reflected as a non-reassuring fetal status during fetal heart rate monitoring. External fetal monitoring can be used as an indicator of fetal well-being, and having a reassuring fetal heart rate is associated with adequate oxygenation and perfusion of the fetus. Fetal heart rate monitoring can be used as an additional vital sign that may help in the management of the maternal condition and guide the decision to move toward additional invasive interventions if needed. As long as the fetal status is reassuring, tolerating a maternal SpO2 between 92% and 96% is prudent and might prevent detrimental outcomes associated with invasive interventions that could negatively affect both mother and baby.

Furthermore, tolerating a lower maternal SpO2 may prevent unnecessary fetal interventions that could happen at time of intubation or extracorporeal membrane oxygenation (ECMO) cannulation, which could be challenging depending on the maternal characteristics. In many instances with difficult intubations, maternal O2 saturation can transiently drop as low as 60% to 70% and is often associated with changes in variability and decelerations on the fetal monitor. Sustained nonreassuring fetal status often warrants acute interventions such as emergent cesarean delivery, which carries significant additional morbidity to the mother on top of her acute respiratory failure secondary to COVID-19. More so, in cases of very preterm pregnancies, a classical cesarean delivery may be indicated, which carries an increased risk of bleeding and long-term implications for future pregnancies.

Conclusion
An SpO2 below 95% in a pregnant individual with COVID-19 should prompt evaluation by a healthcare provider and may require inpatient admission. For pregnant individuals on supplemental O2 for acute respiratory failure secondary to COVID-19 infection, there is a lack of convincing evidence supporting the current recommended SpO2 of ≥95%. We suggest maintaining SpO2 in a range of 92% to 96% in critically ill individuals admitted to the hospital on O2 supplementation.

In the setting of reassuring fetal heart rate monitoring, this could possibly prevent unnecessary invasive interventions including endotracheal intubation with mechanical ventilation and ECMO. This is especially significant when the decision to escalate these measures is based on the concern for maintaining fetal oxygenation rather than supporting the mother’s respiratory status. In these situations, external fetal monitoring can be used as an additional noninvasive tool to monitor the fetal well-being and reserve invasive interventions for maternal respiratory status indications as long as the fetus is not showing signs of distress.

REFERENCES
1. Society for Maternal-Fetal Medicine. Management considerations for pregnant patients with COVID-19. 2020. Available at: https://s3.amazonaws.com/cdn.sfmw.org/media/2734/SMMF_COVID_Management_of_COVID_pos_preg_patients_2-2-21_(final).pdf. Accessed April 30, 2020.
2. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy. 2020. Available at: https://www.rcog.org.uk/coronavirus-pregnancy. Accessed September 21, 2021.
3. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. Int J Gynaecol Obstet 2020;149:273–86.
4. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) is suspected. 2020. Available at: https://www.who.int/publications/i/item/10665-332299. Accessed September 22, 2021.
5. Pacheco LD, Saad AF, Saade G. Early acute respiratory support for pregnant patients with coronavirus disease 2019 (COVID-19) infection. Obstet Gynecol 2020;136:42–5.
6. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet 2020;149:130–6.
7. Poon LC, Yang H, Dumont S, et al. ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update. Ultrasound Obstet Gynecol 2020;55:949–62.
8. Bhatia PK, Byjani G, Mohammed S, Sethi P, Bhanj P. Acute respiratory failure and mechanical ventilation in pregnant patient: a narrative review of literature. J Anaesthesiol Clin Pharmacol 2016;32:431–9.
9. Catanzarite V, Willms D, Wong D, Landers C, Cousins L, Schrimmer D. Acute respiratory distress syndrome in pregnancy and the puerperium: causes, courses, and outcomes. Obstet Gynecol 2001;97:760–4.
10. Dashraath P, Wong JLI, Lim MXX, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020;222:521–31.
11. Di Mascio D, Khali A, Sacone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020;2:100107.
12. Wong SF, Chow KM, Leung TN, et al. Prenatal and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004;191:292–7.
13. Mallampalli A, Powner DJ, Gardner MO. Cardiopulmonary resuscitation and somatic support of the pregnant patient. Crit Care Clin 2004;20:747–61.
14. Van Hook JW. Acute respiratory distress syndrome in pregnancy. Semin Perinatol 1997;21:320–7.
15. Graves CR. Pneumonia in pregnancy. Clin Obstet Gynecol 2010;53:329–36.
16. Levinson G, Shinder SM, DeLormier AA, Steffenson JL. Effects of maternal hyperventilation on uterine blood flow and fetal oxygenation and acid-base status. Anesthesiology 1974;40:340–7.
17. Sobrevilla LA, Cassinelli MT, Carcelen A, Malaga JM. Human fetal and maternal oxygen tension and acid-base status during delivery at high altitude. Am J Obstet Gynecol 1971;111:1111–8.
18. Grocott MP, Martin DS, Levett DZ, et al. Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med 2009;360:140–9.
19. Singh S, McIlvennan A, England A, Simons R. A validation study of the CEMACH recommended modified early obstetric warning system (MEOWS). Anaesthesia 2012;67:12–8.
20. Shields LE, Wiesner S, Klein C, Pelletreau B, Hedriana HL. Use of Maternal Early Warning Trigger tool reduces maternal morbidity. Am J Obstet Gynecol 2016;214:527.e1–6.
early warning score: secondary analysis of the Intensive Care National Audit and Research Centre Case Mix Programme database. Anaesthesia 2013;68:354–67.
22. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;48:e440–69.
23. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet 2018;391:1693–705.
24. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ 2018;363:k4169.
25. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–8.
26. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363:1107–16.
27. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med 2019;380:1997–2008.
28. Gattinoni L, Chiuriello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020;46:1099–102.
29. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020;323:2329–30.
30. Wendel García PD, Aguirre-Bermeo H, Buehler PK, et al. Implications of early respiratory support strategies on disease progression in critical COVID-19: a matched subanalysis of the prospective RISC-19-ICU cohort. Crit Care 2021;25:175.
31. Sarma A, Caffee CS. Prone positioning in awake, nonintubated patients with COVID-19: necessity is the mother of invention. JAMA Intern Med 2020;180:1539–40.
32. Thompson AE, Ranard BL, Wei Y, Jelic S. Prone positioning in awake, nonintubated patients with COVID-19 hypoxic respiratory failure. JAMA Intern Med 2020;180:1537–9.
33. Del Rio C, Malani PN, Omer SB. Confronting the delta variant of SARS-CoV-2, summer 2021. JAMA 2021;326:1001–2.
34. Wang AM, Berry M, Moutos CP, et al. Association of the Delta (B.1.617.2) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with pregnancy outcomes. Obstet Gynecol 2021;138:838–41.
35. World Health Organization. Weekly epidemiological update on COVID-19. 2021. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19. Accessed September 21, 2021.
36. Martin CB Jr. Normal fetal physiology and behavior, and adaptive responses with hypoxemia. Semin Perinatol 2008;32:239–42.
37. Phelan JP. Labor admission test. Clin Perinatol 1994;21:879–85.
38. Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. Obstet Gynecol 2002;99:129–34.
39. Sahin FK, Koken G, Cosar E, et al. Obstructive sleep apnea in pregnancy and fetal outcome. Int J Gynaecol Obstet 2008;100:141–6.
40. Liu S, Liston RM, Joseph KS, et al. Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term. CMAJ 2007;176:455–60.
41. Ghazi A, Karim F, Hussain AM, Ali T, Jabbar S. Maternal morbidity in emergency versus elective caesarean section at a tertiary care hospital. J Ayub Med Coll Abbottabad 2012;24:10–3.
42. Patterson LS, O’Connell CM, Baskett TF. Maternal and perinatal morbidity associated with classic and inverted T cesarean incisions. Obstet Gynecol 2002;100:633–7.
43. Kan A. Classical cesarean section. Surg J (N Y) 2020;6(Suppl 2):S98–103.
44. Halperin ME, Moore DC, Hannah WJ. Classical versus low-segment transverse incision for preterm caesarean section: maternal complications and outcome of subsequent pregnancies. Br J Obstet Gynaecol 1988;95:990–6.
45. Chauhan SP, Magann EF, Wiggs CD, Barrilleaux PS, Martin JN Jr. Pregnancy after classic cesarean delivery. Obstet Gynecol 2002;100:946–50.